{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000003","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.959931+00:00","generated_at":"2026-06-07T02:21:30.677117+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Novocure reports preliminary 2023 revenue $509M (-5% YoY); NSCLC PMA submitted to FDA","bullets":["Preliminary FY 2023 net revenues $509.3M, down 5% YoY on reduced US claim collections.","Q4 2023 net revenues $133.8M, up 4% YoY; US contributed $91.3M, Germany $14.7M.","1,564 prescriptions in Q4 (+14% YoY); 3,755 active patients (+9% vs Q4 2022).","PMA application for TTFields in NSCLC submitted to FDA/PMDA in December 2023.","Appointed Dr. Nicolas Leupin as Chief Medical Officer effective Jan 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000003","json":"https://secwatch.observer/filing/0001645113-24-000003.json","markdown":"https://secwatch.observer/filing/0001645113-24-000003.md","text":"https://secwatch.observer/filing/0001645113-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/0001645113-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/nvcr-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:21:30.677117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a7908f833031f3f796ab259fe705cd2e572a49b","claim":"NovoCure Ltd reported the quarter and year ended December 31, 2023 results: revenue $509.3 million.","evidence_excerpt":"--- EX-99.1 (EX-99.1) --- Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D. appointed as","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/0001645113-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$509.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}